ArticleScientific reports2026
Apparent diffusion coefficient and intravoxel incoherent motion-derived true diffusion serve as early non-contrast longitudinal biomarkers of neoadjuvant chemotherapy response.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Locally advanced breast cancer (LABC) frequently requires neoadjuvant chemotherapy (NAC), and early, non-contrast imaging biomarkers are of increasing clinical interest for monitoring treatment response. Diffusion-weighted imaging (DWI) and intravoxel incoherent motion (IVIM) MRI provide quantitative measures of tumour microstructure without gadolinium administration. To evaluate whether the apparent diffusion coefficient (ADC) and true diffusion (Dt) derived from IVIM can serve as early non-contrast imaging biomarkers of NAC response in patients with LABC. Fourteen women with biopsy-proven LABC underwent MRI at baseline (T0), after the first NAC cycle (T1), and after the third cycle (T2). ADC was calculated from b = 0 and 1000 s/mm², while Dt, Dp, and f were obtained using a full bi-exponential IVIM model incorporating all b-values (0-1000 s/mm²). Only four patients completed all three MRI timepoints. Tumour diameter and diffusion parameters were compared across time. At baseline, ADC and Dt were significantly lower in malignant lesions compared with contralateral fibroglandular tissue (p < 0.01). Following NAC, mean tumour ADC increased by 27.2% at T1 and 39.5% at T2, accompanied by progressive tumour size reduction (50.9% at T2). Dt demonstrated a similar upward trend. Perfusion-related IVIM parameters (Dp and f) showed no consistent differences. ROC analysis demonstrated high discriminatory performance of ADC for differentiating invasive ductal carcinoma from normal tissue (AUC = 1.00), although this finding must be interpreted cautiously given the small sample size. ADC and Dt showed early increases following NAC that paralleled reductions in tumour size, supporting their potential as practical, contrast-free imaging biomarkers of treatment-related microstructural changes. However, the limited number of complete longitudinal datasets (n = 4) and the pilot nature of the study require cautious interpretation. Larger prospective studies are needed to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.